OMCL logo

OMNICELL INC

OMCLNASDAQ
πŸ† #2179 by market capEarnings Oct 28 Β· PreUS Equity
$34.05β–Ό $0.26 (βˆ’0.76%)
πŸŒ™ After hours$34.20β–² 0.44%Regular close Β· extended-hours price shown
πŸ””
Track OMCL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.8%
7dβ–² 3.2%
14dβ–² 5.1%
30dβ–Ό 3.2%
ytdβ–Ό 24.8%
1yβ–² 11.7%
🏦Market Cap
$1.55B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+8.4%
Slowing
πŸ“ŠGross Margin
44.8%
Healthy
πŸ’΅FCF Margin
10.0%
Moderate
βš–οΈP/S Ratio
1.2x
Cheap
Otter Score
80
Good

Trading Snapshot

Day Range
$33.64 – $34.59
52-Week Range
$29.06 – $55.00
Volume
$2.34B
Avg Volume
$2.87B
Shares Outstanding
45.5M
Next Earnings
Nov 16, 2026

Fundamentals Snapshot

Annual Revenue
$1.18B
Last Q Revenue
$312M
P/E Ratio
38.8
P/S Ratio
1.2x
EPS (TTM)
$0.85
Dividend Yield
β€”
Dilution (1yr)
βˆ’2.8%

Why Investors Own OMCL

  • βœ“High-growth profile β€” revenue up +52.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 54% gross margin and 30% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OMCL logo

OMNICELL INC

OMCL
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.2Bβ–² +6.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
42.9%β–² +1.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$12Mβ–² +3361.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$87Mβ–Ό βˆ’42.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
45.0Mβ–Ό βˆ’2.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$8Mβ–² +$6M YoY
StockOtter Β· stockotter.space

About OMNICELL INC

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
80/100

Analyst Ratings

β“˜
Consensus
Buy
14 analysts
Strong Buy3
Buy9
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Zacks Investment ResearchΒ·14d ago

Here's Why Omnicell (OMCL) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

PRNewsWireΒ·27d ago

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.

Business WireΒ·Aug 31

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.

Zacks Investment ResearchΒ·Aug 24

Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Motley FoolΒ·Aug 20

Omnicell President Sells 6,753 Shares

The disposal comprised 6,753 shares representing a total transaction value of ~$250,000. The transaction reduced the insider's direct equity holdings by 4%.

Defense WorldΒ·Aug 20

Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL

Bank of America Corp DE raised its holdings in Omnicell, Inc. (NASDAQ: OMCL) by 31.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fir